Oncodetect, Inc. 

In quest for superior diagnosis and treatment


Innovative diagnosis and therapeutic strategies

HomeDevelopment of recombinant p21 protein as a viable therapy for AIDSINVESTORS NEEDEDSCIENCE CONSULTANTNEWSExecutive SummaryBreast Cancer testp21 drug development


Ashwani Khanna Ph.D. Chief Scientific Officer of a start up Biotech company OncoDetect, also Associate Professor of Medicine at University of Maryland, Baltimore to present "DEVELOPMENT OF CYCLIN KINASE INHIBITOR AS A POTENT IMMUNOSUPPRESSIVE DRUG" at The International Society for Heart and Lung Transplantation 29th Annual Meeting and Scientific Sessions in Paris on 4/24/2009 in Title: Concurrent Session 29: Novel Therapeutics Targeting Rejection and Injury. This study describes the development of cyclin kinase inhibitor p21 as a potent anti-rejection therapeutic agent for organ transplant recipients. Currently clinically used immunosuppressive agents; Cyclosporine, Tacrolimus and Sirolimus though have considerably reduced the rejection rates but have failed to promote long-term graft survival due to inherent side effects such as renal dysfunction, viral infections and malignancy. Use of recombinant p21 by virtue of its anti-proliferative, anti-inflammatory and anti-cancer properties as well as inhibition of viral replication will not only provide optimal immunosuppression but eliminate significant side effects allowing prolongation of transplant survival, the desire of transplantation physicians, surgeons and biologists.